Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia

Phase 1

• Conditions: Leukemia, B-Cell
• Interventions: Biological: CD19-targeted CART cells

• Registration Number: NCT03599375
• Lead Sponsor: jiuwei cui

Brief Summary

This study aims to evaluate the safety and clinical activity of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in treating patients with recurrent or refractory CD19 positive B cell ccute lymphoblastic leukemia,and dynamically observe the changes of CAR-T in patients and the residual tumor.

Detailed Description

In this single-center, open-label, single-arm, prospective clinical trial, a total of 20 recurrent or refractory CD19+ B cell acute lymphoblastic leukemia patients will be enrolled.After recruiting eligible patients,autologous peripheral blood mononuclear cells(PBMCs) will be purified from whole blood.The CD3+ T cells were subsequently selected and re-stimulated by anti-CD3 and anti-CD28 monoclonal antibodies.T cells will be transduced with lentiviral vector for the generation of the CD19 CART cell and administered by i.v. injection.The purpose of current study is to determine the safety and clinical efficacy of CD19 CAR T cells therapy in patients with recurrent or refractory CD19+ ALL.

Study Timeline

• Study First Submitted: 2018-07-15
• Study First Submitted QC: 2018-07-15
• Study First Posted: 2018-07-26
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-24
• Last Update Posted: 2019-02-26
• Study Start: 2019-05-01
• Primary Completion: 2020-12-30
• Study Completion: 2021-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Recurrent or refractory B cell derived acute lymphoblastic leukemia (ALL)
• Patients who have failed at least one line of a standard treatment without effective treatment measures at present
• CD19 expression on the surface of B-ALL cells must be detected
• KPS>80
• Life expectancy >3 months
• Patients must have adequate cardiac function (no electrocardiogram with obvious abnormality, LVEF≥50%),adequate pulmonary function as indicated by room air oxygen saturation of > 90%, and adequate renal function (Cr≤2.5 times of the normal range)
• The alanine aminotransferase (ALT) and the aspartate aminotransferase (AST)≤ 3 times of the normal range, and the total bilirubin (TBIL)≤2.0mg/dl(34.2umol/L)
• Hemoglobin(Hgb)≥80g/L
• Without contraindication of apheresis and cell isolation
• Patients and their families volunteer to participate in the research with signed written informed consent

Exclusion Criteria

.Other concurrent severe and/or uncontrolled medical conditions: patients with another primary malignant disease; another severe and/or life-threatening medical disease.

• Evidence of uncontrolled current serious active infection
• HIV/HBV/HCV infection
• Pregnancy and nursing females
• Systemic glucocorticoid therapy within one week

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
B-ALL treated with CD19 CART cell	CD19-targeted CART cells	The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.

Primary Outcome Measures

Name	Time	Method
overall response rate(ORR)	Participants will be followed for the duration of the treatment, with an expected average of 3 months.	ORR is defined as the proportion of partial responses plus complete responses.

Secondary Outcome Measures

Name	Time	Method
Progression free survival(PFS)	15 years	Progression-free survival is defined as the time from enrollment to first observation of progression or date of death (from any cause).
Overall survival(OS)	15 years	Overall survival, defined as the time from enrollment until death due to any cause. For patients who do not die, time to death will be censored at the time of last contact.